tadalafil 2.5 mg
1 INDICATIONS AND USAGE Tadalafil is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ). the signs and symptoms of benign prostatic hyperplasia (BPH) (1.2). ED and the signs and symptoms of BPH (ED/BPH) (1.3). If tadalafil is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks (1.4) . 1.1 erectile dysfunction Tadalafil tablets are indicated for the treatment of erectile dysfunction (ED). 1.2 benign prostatic hyperplasia Tadalafil tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). 1.3 erectile dysfunction and benign prostatic hyperplasia Tadalafil tablets are indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH). 1.4 Limitation of Use If tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of tadalafil tablets decreases from 4 weeks until 26 weeks, and the incremental benefit of tadalafil tablets beyond 26 weeks is unknown [see Clinical Studies (14.3) ] .
amneal pharmaceuticals ny llc
ROUND WHITE C1
Related Pills
tadalafil 20 mg
amneal pharmaceuticals ny llc
tadalafil 20 mg
amneal pharmaceuticals ny llc
tadalafil 20 mg
amneal pharmaceuticals ny llc
tadalafil 10 mg
amneal pharmaceuticals ny llc
tadalafil 5 mg
amneal pharmaceuticals ny llc
tadalafil 2.5 mg
amneal pharmaceuticals ny llc
clopidogrel 75 MG Oral Tablet
Accord Healthcare Inc.
lamotrigine tablet
cipla usa inc.
paroxetine tablet film coated
zydus pharmaceuticals (usa) inc.
potassium 750 mg
mylan pharmaceuticals inc.
potassium 750 mg
mylan pharmaceuticals inc.
lamotrigine tablet
cipla usa inc.
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied
TADALAFIL Tablets USP, 2.5 mg are supplied as white to off-white, round, biconvex, film-coated tablets debossed with “C1” on one side and plain on the other. They are available as follows: Bottles of 30: NDC 69238-1346-3
TADALAFIL Tablets USP, 5 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “A13” on one side and plain on the other. They are available as follows: Bottles of 30: NDC 69238-1347-3
TADALAFIL Tablets USP, 10 mg are supplied as yellow colored, round, biconvex, film-coated tablets debossed with “AC” above “06” on one side and plain on the other. They are available as follows: Bottles of 30: NDC 69238-1348-3
TADALAFIL Tablets USP, 20 mg are supplied as yellow colored, oval, biconvex, film-coated tablets debossed with “AA” on one side and “09” on the other. They are available as follows: Bottles of 30: NDC 69238-1349-3 16.2 Storage Store at 20º to 25ºC (68º to 77ºF); excursions permitted between 15° and 30°C (59° and 86°F) [see USP Controlled Room Temperature]. Keep this and all medications out of reach of children.
More pills like ROUND C1